-
-
-
-
-
-
-
Polyrizon secures first U.S. clinical site for allergy blocker trial
-
-
-
-
-
-
-
LDB Capital Corp. Announces Definitive Agreement for Proposed Qualifying Transaction with Eventer Technologies Ltd.
-
-
-
-
-
-
-
Polyrizon names allergy blocker product NASARIX
-
-
-
-
-
-
-
Polyrizon completes manufacturing milestone for nasal spray platform
-
-
-
-
-
-
-
Polyrizon retains NASDAQ listing after hearings panel review
-
-
-
-
-
-
-
Polyrizon Ltd (PLRZ) Announces $17M Private Placement at $0.48/unit
-
-
-
-
-
-
-
Polyrizon Ltd (PLRZ) Files Divisional Patent Application for Its Innovative Trap & Target (T&T) Intranasal Drug Delivery Platform
-
427,074 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

